These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
540 related articles for article (PubMed ID: 26059964)
1. Safety of anticoagulant treatment in cancer patients. Wilts IT; Bleker SM; Van Es N; Büller HR; Di Nisio M; Kamphuisen PW Expert Opin Drug Saf; 2015 Aug; 14(8):1227-36. PubMed ID: 26059964 [TBL] [Abstract][Full Text] [Related]
2. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice. den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552 [TBL] [Abstract][Full Text] [Related]
3. LMWH in cancer patients with renal impairment - better than warfarin? Bauersachs RM Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971 [TBL] [Abstract][Full Text] [Related]
4. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism. Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949 [TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142 [TBL] [Abstract][Full Text] [Related]
6. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891 [TBL] [Abstract][Full Text] [Related]
7. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer. Kirkilesis GI; Kakkos SK; Tsolakis IA Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186 [TBL] [Abstract][Full Text] [Related]
8. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Pritchard ER; Murillo JR; Putney D; Hobaugh EC J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375 [TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism in cancer patients. Petralia GA; Kakkar AK Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799 [TBL] [Abstract][Full Text] [Related]
10. Prevention of deep vein thrombosis in cancer patients. Lee AY Semin Thromb Hemost; 2007 Oct; 33(7):699-706. PubMed ID: 18000798 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulant use in cancer patients. Trujillo-Santos J; Monreal M Expert Opin Pharmacother; 2011 Feb; 12(3):351-62. PubMed ID: 21254944 [TBL] [Abstract][Full Text] [Related]
12. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929 [TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. Hull RD; Townshend G Thromb Haemost; 2013 Jul; 110(1):14-22. PubMed ID: 23615656 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis. Ross JA; Miller MM; Rojas Hernandez CM Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037 [TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism in cancer patients. Deng A; Galanis T; Graham MG Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915 [TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in lymphoma: how effectively are we treating patients? Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801 [TBL] [Abstract][Full Text] [Related]
17. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism. Patel A; Williams H; Baer MR; Zimrin AB; Law JY Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Louzada ML; Majeed H; Wells PS Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517 [TBL] [Abstract][Full Text] [Related]
19. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314 [TBL] [Abstract][Full Text] [Related]
20. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis. Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]